StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for OVID yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $2.63 | $2.41 | -8.37% | 1.4M |
| 05-19 | $2.39 | $2.40 | +0.42% | 1.6M |
| 05-20 | $2.40 | $2.39 | -0.42% | 0.9M |
| 05-21 | $2.34 | $2.44 | +4.27% | 0.7M |
| 05-22 | $2.46 | $2.47 | +0.41% | 1.3M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $7.25M | $6.53M | $6.40M |
Operating Income | $-17.85M | $-42.44M | $-30.15M | $-17.62M |
Net Income | $-16.99M | $-17.41M | $-27.08M | $-4.68M |
EPS (Diluted) | Not available | Not available | Not available | Not available |
Total Assets | $225.63M | $150.93M | $63.85M | $77.43M |
Total Liabilities | $27.36M | $20.27M | $19.15M | $21.64M |
Cash & Equivalents | $94.06M | $13.15M | $20.61M | $28.41M |
Free Cash Flow OCF − CapEx | Not available | $-38.33M | $-27.93M | $-15.05M |
Shares Outstanding | 167.27M | 130.18M | 71.15M | 71.11M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.